A report found a significantly higher kynurenine/tryptophan ratio in NSCLC patients with early progression on nivolumab, suggesting that IDO might contribute to primary resistance to anti-PD-1 monoclonal antibodies (207). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.